|
| 36634852 | Interobserver variation in clinical target volume (CTV) delineation for stereotactic radiotherapy to non-spinal bone metastases in prostate cancer: CT, MRI and PET/CT fusion. | Radiother Oncol | 2023 |
| 37808453 | ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy. | Clin Transl Radiat Oncol | 2023 |
| 37507334 | A planning-based feasibility study of MR-Linac treatment for anal cancer radiation therapy. | Med Dosim | 2023 |
| 37420000 | Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. | Br J Cancer | 2023 |
| 37251620 | ESTROÂ ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. | Clin Transl Radiat Oncol | 2023 |
| 37444565 | Beyond the Knife in Renal Cell Carcinoma: A Systematic Review-To Ablate or Not to Ablate? | Cancers (Basel) | 2023 |
| 36818674 | A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy. | Front Oncol | 2023 |
| 35142815 | Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2022 |
| 35534398 | Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis. | Clin Oncol (R Coll Radiol) | 2022 |
| 35688662 | Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial. | Eur Urol | 2022 |
| 35656509 | Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice. | Front Oncol | 2022 |
| 36452501 | Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive bladder cancer following neoadjuvant chemotherapy. | Front Oncol | 2022 |
| 35906833 | A pilot study investigating the role of <sup>18</sup> F-FDG-PET in the early identification of chemoradiotherapy response in anal cancer. | J Med Radiat Sci | 2022 |
| 35017008 | Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. | Int J Radiat Oncol Biol Phys | 2022 |
| 35277316 | The dosimetric advantages of perirectal hydrogel spacer in men with localized prostate cancer undergoing stereotactic ablative radiotherapy (SABR). | Med Dosim | 2022 |
| 33384271 | Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer. | Eur Urol Focus | 2021 |
| 33903651 | A phantom study to contrast and compare polymer and gold fiducial markers in radiotherapy simulation imaging. | Sci Rep | 2021 |
| 33898783 | Exploratory models comparing ethiodized oil-glue and gold fiducials for bladder radiotherapy image-guidance. | Phys Imaging Radiat Oncol | 2021 |
| 33561506 | Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study. | Int J Radiat Oncol Biol Phys | 2021 |
| 33632752 | Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. | BMJ Open | 2021 |
| 33549359 | Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer. | Eur Urol | 2021 |
| 34977691 | A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer. | Eur Urol Open Sci | 2021 |
| 34407860 | Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study. | Trials | 2021 |
| 34489210 | Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5Â yr in the CHHiP trial (CRUK/06/016). | Eur Urol Oncol | 2021 |
| 34678156 | A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. | Lancet Oncol | 2021 |
| 34794989 | Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study. | BMJ Open | 2021 |
| 33316362 | Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. | Int J Radiat Oncol Biol Phys | 2021 |
| 33432719 | Proximal seminal vesicle displacement and margins for prostate cancer radiotherapy. | J Med Radiat Sci | 2021 |
| 33249744 | Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. | BJU Int | 2021 |
| 33326257 | Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). | J Clin Oncol | 2021 |
| 32423621 | Clinical Outcomes of Stereotactic Body Radiotherapy With Immediate Versus Delayed Hormone Therapy in Men With Oligometastatic Recurrence of Prostate Cancer. | Clin Oncol (R Coll Radiol) | 2020 |
| 31753752 | EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>â¿ </sup>: Under the Auspices of the EAU-ESMO Guidelines Committees. | Eur Urol | 2020 |
| 31767473 | A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer. | Radiother Oncol | 2020 |
| 32891600 | Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. | Eur Urol Oncol | 2020 |
| 32747153 | Spine and Non-spine Bone Metastases - Current Controversies and Future Direction. | Clin Oncol (R Coll Radiol) | 2020 |
| 32154393 | Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancer. | Tech Innov Patient Support Radiat Oncol | 2020 |
| 32446863 | Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. | Eur Urol | 2020 |
| 30528653 | Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL). | Int J Radiat Oncol Biol Phys | 2019 |
| 32072028 | Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. | Clin Transl Radiat Oncol | 2019 |
| 31740927 | EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committeesâ¿ . | Ann Oncol | 2019 |
| 30251049 | The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial. | World J Urol | 2019 |
| 31385650 | The changing landscape of head and neck cancer radiotherapy patients: is high-risk, prolonged feeding tube use indicative of on-treatment weight loss? | J Med Radiat Sci | 2019 |
| 31178346 | Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity. | Clin Oncol (R Coll Radiol) | 2019 |
| 31176447 | New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly. | Clin Radiol | 2019 |
| 31537406 | Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. | Eur Urol | 2019 |
| 31507035 | Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. | BJU Int | 2019 |
| 31563410 | Patterns of recurrence after prostate bed radiotherapy. | Radiother Oncol | 2019 |
| 30777253 | Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer. | J Med Imaging Radiat Sci | 2019 |
| 30908894 | High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes. | J Med Imaging Radiat Oncol | 2019 |
| 30788497 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ¿ . | Ann Oncol | 2019 |